Gossamer Bio Inc GOSS
News
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval